| Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma R Reschke, J Yu, BA Flood, EF Higgs, K Hatogai, TF Gajewski Journal for immunotherapy of cancer 9 (9), 2021 | 112 | 2021 |
| Dendritic cells can prime anti-tumor CD8+ T cell responses through major histocompatibility complex cross-dressing BW MacNabb, X Chen, S Tumuluru, J Godfrey, DN Kasal, J Yu, ... Immunity 55 (6), 982-997. e8, 2022 | 109 | 2022 |
| Wild-type U2AF1 antagonizes the splicing program characteristic of U2AF1-mutant tumors and is required for cell survival DL Fei, H Motowski, R Chatrikhi, S Prasad, J Yu, S Gao, CL Kielkopf, ... PLoS Genetics 12 (10), e1006384, 2016 | 107 | 2016 |
| Expression profiling of primary and metastatic ovarian tumors reveals differences indicative of aggressive disease AS Brodsky, A Fischer, DH Miller, S Vang, S MacLaughlan, HT Wu, J Yu, ... PloS one 9 (4), e94476, 2014 | 73 | 2014 |
| COVIDOSE: a phase II clinical trial of low‐dose tocilizumab in the treatment of noncritical COVID‐19 pneumonia GW Strohbehn, BL Heiss, SJ Rouhani, JA Trujillo, J Yu, AJ Kacew, ... Clinical Pharmacology & Therapeutics 109 (3), 688-696, 2021 | 54 | 2021 |
| Checkpoint blockade–induced dermatitis and colitis are dominated by tissue-resident memory T cells and Th1/Tc1 Cytokines R Reschke, JW Shapiro, J Yu, SJ Rouhani, DJ Olson, Y Zha, TF Gajewski Cancer Immunology Research 10 (10), 1167-1174, 2022 | 47 | 2022 |
| Severe COVID-19 induces autoantibodies against angiotensin II that correlate with blood pressure dysregulation and disease severity PS Briquez, SJ Rouhani, J Yu, AR Pyzer, J Trujillo, HL Dugan, ... Science Advances 8 (40), eabn3777, 2022 | 41 | 2022 |
| COVIDOSE: Low-dose tocilizumab in the treatment of Covid-19 GW Strohbehn, BL Heiss, SJ Rouhani, JA Trujillo, J Yu, AJ Kacew, ... medRxiv, 2020.07. 20.20157503, 2020 | 25 | 2020 |
| Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions A Major, J Yu, N Shukla, Y Che, TG Karrison, R Treitman, MK Kamdar, ... Blood advances 7 (16), 4528-4538, 2023 | 21 | 2023 |
| Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies SJ Rouhani, J Yu, D Olson, Y Zha, A Pezeshk, A Cabanov, AR Pyzer, ... Journal for immunotherapy of cancer 10 (6), 2022 | 16 | 2022 |
| Total Survivin and acetylated Survivin correlate with distinct molecular subtypes of breast cancer E Yakirevich, A Samkari, MP Holloway, S Lu, K Singh, J Yu, MA Fenton, ... Human pathology 43 (6), 865-873, 2012 | 15 | 2012 |
| Lymphatic coagulation and neutrophil extracellular traps in lung-draining lymph nodes of COVID-19 decedents ME MacDonald, RK Weathered, EC Stewart, AI Magold, A Mukherjee, ... Blood Advances 6 (24), 6249-6262, 2022 | 14 | 2022 |
| Severe COVID-19 infection is associated with aberrant cytokine production by infected lung epithelial cells rather than by systemic immune dysfunction SJ Rouhani, JA Trujillo, AR Pyzer, J Yu, J Fessler, A Cabanov, EF Higgs, ... Research square, 2021 | 12 | 2021 |
| Pembrolizumab for the treatment of disease relapse after allogeneic hematopoietic stem cell transplantation J Godfrey, H Liu, J Yu, M Tallarico, E Curran, A Artz, PA Riedell, W Stock, ... Blood Advances 7 (6), 963-970, 2023 | 10 | 2023 |
| CD5 Gene Signature Identifies Diffuse Large B-Cell Lymphomas Sensitive to Brutonʼs Tyrosine Kinase Inhibition A Cooper, S Tumuluru, K Kissick, G Venkataraman, JY Song, A Lytle, ... Journal of Clinical Oncology 42 (4), 467-480, 2024 | 9 | 2024 |
| TIGIT is a key inhibitory checkpoint receptor in lymphoma J Godfrey, X Chen, N Sunseri, A Cooper, J Yu, A Varlamova, D Zarubin, ... Journal for ImmunoTherapy of Cancer 11 (6), 2023 | 9 | 2023 |
| Primary results from TAIL, a global single-arm safety study of atezolizumab (atezo) monotherapy in a diverse population of patients with previously treated advanced non-small … A Ardizzoni, S Azevedo, BR Viquiera, DR Abreu, J Alatorre-Alexander, ... Annals of Oncology 30, v920-v921, 2019 | 9 | 2019 |
| Checkpoint blockade–induced dermatitis and colitis are dominated by tissue-resident memory T cells and Th1/Tc1 cytokines. Cancer Immunol Res. 2022; 10 (10): 1167–1174. doi: 10 … R Reschke, JW Shapiro, J Yu, SJ Rouhani, DJ Olson, Y Zha, TF Gajewski CIR-22-0362, 0 | 7 | |
| Poor survival outcomes of checkpoint inhibitors for B-cell lymphomas relapsing after or refractory to CAR T-cell therapy: a real-world cohort from 15 US academic institutions A Major, J Yu, ND Shukla, R Treitman, MK Kamdar, BM Haverkos, ... Blood 140 (Supplement 1), 1328-1331, 2022 | 6 | 2022 |
| Student-driven approaches to undergraduate medical research: a peer-led symposium C Yee, AM Wu, CM Wu, RV Thakore, PB Greenberg Rhode Island Medical Journal 99 (8), 31, 2016 | 6 | 2016 |
Dennis FeiStemSynergy Therapeutics在 stemsynergy.com 的电子邮件经过验证
